Since this time, TDP-43 aggregation is now considered to be a general pathological marker for ALS and FTD (Saberi et al., 2015), as well as Alzheimer’s disease (Josephs et al., 2015), Parkinson’s disease (Nakashima-Yasuda et al., 2007), traumatic brain injuries (Johnson et al., 2011) and within the normal aging brain (Uchino et al., 2015). This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.